Vimarsana
Biggest News Aggregation in the World

Korey Capozza News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Korey Capozza. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Korey Capozza Today - Breaking & Trending Today

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis - Vimarsana News

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease... | March 21, 2023

Dupixent (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis - Vimarsana News

Dupixent (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

21.03.2023 - Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo Patients treated with Dupixent ...

LEO Pharma A/S: LEO Pharma Announces European Commission Approval of Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents - Vimarsana News

LEO Pharma A/S: LEO Pharma Announces European Commission Approval of Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents

Adtralza, a biologic that targets and neutralizes the interleukin (IL)-13 cytokine1, is now approved in Europe for adolescents with moderate-to-severe atopic dermatitis.2 NOT FOR DISTRIBUTION

Digital Health Leaders Align on Nocturnal Scratch as a Digital Endpoint for Atopic Dermatitis - Vimarsana News

Digital Health Leaders Align on Nocturnal Scratch as a Digital Endpoint for Atopic Dermatitis

/PRNewswire/ -- The Digital Medicine Society (DiMe) has released a new set of resources to advance the use of digitally measured nocturnal scratch as a...

Digital Medicine Society (DiMe): Digital Health Leaders Align on Nocturnal Scratch as a Digital Endpoint for Atopic Dermatitis - Vimarsana News

Digital Medicine Society (DiMe): Digital Health Leaders Align on Nocturnal Scratch as a Digital Endpoint for Atopic Dermatitis

BOSTON, Sept. 8, 2022 /PRNewswire/ -- The Digital Medicine Society (DiMe) has released a new set of resources to advance the use of digitally measured nocturnal scratch as a meaningful endpoint